Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Haleon PLC Sponsored ADR ( (HLN) ) has shared an update.
On September 5, 2025, Haleon PLC announced the purchase and cancellation of 353,360 ordinary shares as part of the second tranche of its share buyback program initiated on July 31, 2025. This move is part of Haleon’s strategic financial management to optimize its capital structure, potentially enhancing shareholder value and affirming its strong market position in the consumer health industry.
The most recent analyst rating on (HLN) stock is a Hold with a $10.50 price target. To see the full list of analyst forecasts on Haleon PLC Sponsored ADR stock, see the HLN Stock Forecast page.
Spark’s Take on HLN Stock
According to Spark, TipRanks’ AI Analyst, HLN is a Neutral.
Haleon PLC’s overall stock score reflects a strong financial position and operational improvements, particularly in international markets. However, challenges in North America and stagnant revenue growth weigh on the score. Technical indicators and valuation suggest moderate potential for growth, with no significant corporate events impacting the assessment.
To see Spark’s full report on HLN stock, click here.
More about Haleon PLC Sponsored ADR
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with a human touch. Its diverse product portfolio includes categories such as Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. The company is known for its trusted brands like Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren.
Average Trading Volume: 11,417,388
Technical Sentiment Signal: Buy
Current Market Cap: $44.22B
See more data about HLN stock on TipRanks’ Stock Analysis page.